Expression of MicroRNA-1281, C-Reactive Protein, and Renal Function in Individuals with Abdominal Aortic Aneurysm and their Clinical Correlation after Endovascular Repair

Missae, Lais; Rossoni, Breno; Tenorio, Emanuel R.; Ribeiro, Maurício Serra; Tirapelli, Daniela Pretti da Cunha; Joviliano, Edwaldo Edner

doi:10.21470/1678-9741-2020-0268

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to their genetic regulatory function and their high stability in biological fluids, plasmatic miRNAs have been highlighted as being optimal candidates as non-invasive biomarkers. For instance, a recent study found that elevated miRNA-1281 levels might identify patients with follow-up complications [ 8 ]. Most of the current literature is based on predicting post-operative renal disease, with Cystatin C being the recognized early marker of renal failure [ 9 ] ( Figure 1 ).…”

Section: Biomarkers and Compounds In Evar (Treated Disease)mentioning

confidence: 99%

Biomarkers in EndoVascular Aneurysm Repair (EVAR) and Abdominal Aortic Aneurysm: Pathophysiology and Clinical Implications

et al. 2022

View full text Add to dashboard Cite

Circulating biomarkers have been recently investigated among patients undergoing endovascular aortic aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA). Considering the plethora of small descriptive studies reporting potential associations between biomarkers and clinical outcomes, this review aims to summarize the current literature considering both the treated disease (post EVAR) and the untreated disease (AAA before EVAR). All studies describing outcomes of tissue biomarkers in patients undergoing EVAR and in patients with AAA were included, and references were checked for additional sources. In the EVAR scenario, circulating interleukin-6 (IL-6) is a marker of inflammatory reaction which might predict postoperative morbidity; cystatin C is a promising early marker of post-procedural acute kidney injury; plasma matrix metalloproteinase-9 (MMP-9) concentration after 3 months from EVAR might help in detecting post-procedural endoleak. This review also summarizes the current gaps in knowledge and future direction of this field of research. Among markers used in patients with AAA, galectin and granzyme appear to be promising and should be carefully investigated even in the EVAR setting. Larger prospective trials are required to establish and evaluate prognostic models with highest values with these markers.

show abstract

Section: Biomarkers and Compounds In Evar (Treated Disease)mentioning

confidence: 99%